research Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review
JAK inhibitors show promise for treating alopecia areata but have serious side effects.
Search
for
Sort by
Research
30-60 / 1000+ results research INIBIDORES DA JANUS QUINASE PARA O TRATAMENTO DA ALOPECIA AREATA
JAK inhibitors effectively treat severe alopecia areata with manageable side effects.
research Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024
In 2024, the FDA approved 27 innovative small-molecule drugs, with many offering significant treatment improvements.
research Unlocking the Potential of Rosemary in Alopecia: A Narrative Review of Evidence on Mechanism, Applications and Challenges
Rosemary shows promise in treating alopecia, similar to minoxidil, but more research is needed.
research SYSTEMATIC REVIEW OF ORAL JANUS KINASE INHIBITORS IN ALOPECIA AREATA: INSIGHTS FROM 2020 TO 2025 STUDIES
Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.
research Alopecia Areata: Pathogenesis, current treatments, and future perspectives
Alopecia areata causes hair loss due to immune issues, and while new treatments show promise, no universally effective solution exists yet.
research The Burden of Alopecia Areata and Management with Baricitinib in the United Arab Emirates: A Narrative Review
Baricitinib is a promising treatment for alopecia areata in the UAE, but there are challenges with data and access.
research Psychometric Properties of the EQ-5D-5L in Patients with Alopecia Areata
The EQ-5D-5L tool may not accurately measure the impact of alopecia areata on patients' lives.
research Evidence Synthesis Gone Awry: The Perils of Aggregating Ineffective or Unsafe Doses in Alopecia Areata Reviews
Including ineffective or unsafe doses in reviews can lead to misleading conclusions about alopecia areata treatments.
research Estimation of health utility values for alopecia areata
More severe hair loss in alopecia areata greatly impacts patients and caregivers.
research Safety of oral JAK inhibitors in treating alopecia areata: a systematic review and network meta-analysis
Oral JAK inhibitors are safe for alopecia areata, but baricitinib may cause more acne and infections.
research El papel de los inhibidores de JAK en la alopecia areata: revisión de la literatura
JAK inhibitors help treat alopecia areata but have high recurrence after stopping.
research Comparison of Dermatology Life Quality Index Scores in Adults and Adolescents with Alopecia Areata
Alopecia areata affects quality of life more in adolescents than adults.
research JAK-inhibitors in the therapy of comorbid diseases – atopic dermatitis and alopecia areata: literature review and experience of clinical practice
JAK inhibitors effectively treat severe atopic dermatitis and alopecia areata.
research Episodic Neuropathic-Like Musculoskeletal Pain Associated With Ritlecitinib Therapy in Alopecia Universalis: A Case Report
Ritlecitinib may cause severe musculoskeletal pain in some alopecia universalis patients.
research Australasian Society for Dermatology Research Meeting, May 2007
The document suggests a bacteria plays a significant role in acne rosacea and that white hair can regain color after transplant, meriting more research on reversing grey hair.
research 42004 Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.
research Overview of alopecia areata for managed care and payer stakeholders in the United States
Alopecia areata causes hair loss and life quality issues; current treatments are often unsatisfactory, but new drugs like JAK inhibitors show promise.
research Pyroptosis in Alopecia Areata: Synthesizing Emerging Hypotheses and Charting a Path to New Therapies
Targeting pyroptosis may offer new treatments for alopecia areata, but more research is needed.
research Alopecia areata
research Recent Advances in Drug Development for Hair Loss
New treatments for hair loss show promise with advanced therapies and better targeting.
research Association between SQSTM1 dysregulation and risk in alopecia areata: a Mendelian randomization study
SQSTM1 gene issues may increase the risk of alopecia areata.
research Role of Arachidonic Acid in Promoting Hair Growth
Arachidonic acid helps hair grow by increasing growth factors and improving follicle health.
research Clinical Presentations and Comorbidities of Pediatric Alopecia Areata
Pediatric alopecia areata needs more research to understand its characteristics and related conditions.
research New therapies for alopecia areata
New treatments for severe alopecia areata show promise but lack standard approval.
research 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
CTP-543 is generally safe for treating alopecia areata.
research Efficacy and safety of twice-weekly and thrice-weekly dutasteride compared to finasteride in men with androgenetic alopecia: A randomized, investigator-blind, active-controlled, parallel-group pilot study
Thrice-weekly dutasteride improved hair density and thickness more than twice-weekly, but not hair count compared to daily finasteride.
research Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
Deuruxolitinib effectively promotes hair regrowth in adults with alopecia areata.
research Cystathionine β‐synthase‐deficient mice thrive on a low‐methionine diet
Mice with CBS deficiency are healthier on a low-methionine diet.
research Case Report: Hypopituitarism Masquerading As Failure to Thrive in a 75‐Year‐Old Woman
Elderly patients with frailty should be checked for hypopituitarism, as treatment can greatly improve their health and lifespan.